Headquartered in Toronto, ON·Fiscal year ends December·NASDAQ: MSLE·satellos.com
About Satellos Bioscience
Satellos Bioscience Inc. is a clinical-stage, pre-revenue biotechnology company. It develops orally administered small-molecule drugs intended to restore natural muscle repair and regeneration in degenerative muscle diseases.
Its lead candidate, forazapadin (formerly SAT-3247), inhibits adaptor-associated kinase 1 (AAK1). The drug aims to re-establish a biochemical signal that supports muscle regeneration. It is designed as a dystrophin-independent, exon-mutation-agnostic therapy for Duchenne muscular dystrophy (DMD), usable alone or alongside other treatments.
Forazapadin's clinical status:
- **DMD:** It is in two Phase 2 studies.
- BASECAMP: pediatric, placebo-controlled, with 53 boys enrolled. MRI fat fraction is the primary efficacy endpoint, which the company believes could support a potential accelerated approval pathway.
- TRAILHEAD: adult, 12-month, open-label.
- It holds FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations for Duchenne.
- **Facioscapulohumeral muscular dystrophy (FSHD):** The Phase 2 TRAVERSE study is being initiated after FDA IND and Health Canada CTA clearances. Development is partly funded by the FSHD Canada Foundation.
The science comes from muscle stem cell discoveries by co-founder Dr. Michael Rudnicki. Satellos licenses this technology from the Ottawa Hospital Research Institute under a royalty-bearing license. It also uses its proprietary MyoReGenX discovery platform to identify follow-on indications, such as LAMA2- and Collagen VI-related muscular dystrophies.
Satellos operates a single R&D segment. Its shares trade on Nasdaq (MSLE) and the TSX (MSCL). It funds operations through equity offerings, an at-the-market facility of up to USD 50 million, and non-dilutive funding. Updated
Pre-Market Stock Futures: Futures are trading mixed as we get ready to kick off the first-quarter earnings season next week, and, as usual, the big money-center banks and brokerage firms will headline…
Satellos Bioscience Inc. is a clinical-stage, pre-revenue biotechnology company. It develops orally administered small-molecule drugs intended to restore natural muscle repair and regeneration in degenerative muscle diseases.
What is the MSLE stock price target?
The Wall Street consensus 12-month price target for MSLE is $24.17.